Karo Pharma AB (publ)
KARO.ST
Stockholm Stock Exchange60.70
SEK
+0.20
- -
Karo Pharma AB (publ)
KARO.ST
(Stockholm Stock Exchange)
Recent
price
60.70
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Karo Pharma AB (publ) operates as a pan-European consumer healthcare company specializing in pharmaceutical and healthcare products across several key segments including Skin Health, Foot Health, Intimate Health, Digestive Health, and Vitamin & Mineral Supplements. Its core product portfolio features well-established brands such as Decubal, Fungobase, PoxClin, Multi-Gyn, Multi-Mam, Ibux, Paracet, and Viruseptin, encompassing dermatology products for eczema and fungal infections; intimate care products for women's health including bacterial vaginosis and vaginal dryness treatments; as well as over-the-counter pain relief, cough, and cold medications. The company develops innovative formulations with a focus on efficacy and patient compliance and markets its products in over 90 countries through a combination of direct sales organizations and global distributors. Founded in 2006 and headquartered in Stockholm, Sweden, Karo has evolved from a Nordic specialty pharma business into a leading consumer healthcare platform across Europe. In the last 1-2 years, Karo Pharma has undergone significant strategic transformation including its acquisition by KKR in 2025 from the EQT VIII fund, marking a shift to accelerate growth supported by KKR’s global expertise and investment capacity. The company has pursued an aggressive expansion strategy driven by organic growth and targeted mergers and acquisitions, completing eight acquisitions since 2019 to enrich its product portfolio and broaden its geographic reach. Notably, it acquired Sylphar International NV for EUR 290 million and agreed to purchase the topical Lamisil business from Haleon UK Holdings for approximately £240 million, strengthening its presence in dermatology. Karo also divested its Hospital Supply business (Swereco AB) to J2L Holding AB to focus more on consumer health. Partnerships such as licensing agreements with Moberg Pharma further expand its portfolio and commercial capabilities. These operational shifts underscore Karo’s positioning as a diversified consumer health platform with robust digital capabilities and a scalable market presence throughout Europe and beyond.